Lantheus Holdings, Inc.
$102.10$0.00 (0.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $6.7B
- P/E
- 28.7x
- EV / EBITDA
- 17.2x
- Revenue
- $1.5B
- Net margin
- 15.2%
- ROCE
- 20.1%
Price chart
Technical chartScreen technicals →+90.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +1.7%
- 3M
- +1.9%
- 6M
- +6.3%
- 1Y
- +90.5%
- 5Y
- +255.9%
52-week range
Day change $0.00 (0.0%) from $102 to $102 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in LNTH, bought on each weekday since 2021.
News & filings
What Lantheus Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthNet profit more than doubled a year on average over three years.
Concerns (1)
- Net profit fell 25.2% in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Read moreShow less
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 64.6M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $6.7B
- P/E
- 28.7x
- P/B
- 6.1x
- EV / EBITDA
- 17.2x
- EV / Sales
- 4.5x
- P/S
- 4.3x
- 52-week high
- $110.94
- 52-week low
- $53.59
Profitability
- Operating margin
- 20.5%
- Net margin
- 15.2%
- EBITDA margin
- 26.2%
- ROE
- 21.4%
- ROCE
- 20.1%
- ROIC
- 18.4%
- ROA
- 10.5%
- Asset turnover
- 0.69
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.5B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 0.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 18.1%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -25.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $348.6M
Solvency
- Current ratio
- 2.70
- Debt / Equity
- 0.57
- Debt / Assets
- 0.28
- CFO / Net profit
- 1.67
- Cash / Market cap
- 5.4%
Where the revenue went
Of every $100 of FY2025 revenue, $15 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $599.7M |
| Revenue | Gross profit | $941.9M |
| Gross profit | Operating expenses | $626.4M |
| Gross profit | Operating income | $315.6M |
| Operating income | Pretax income | $313.8M |
| Operating income | Interest and other expense | $1.8M |
| Pretax income | Tax and other | $80.2M |
| Pretax income | Net income | $233.6M |
Revenue and net profit
Revenue grew 0.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $935.1M | $28.1M |
| FY2023 | $1.3B | $326.7M |
| FY2024 | $1.5B | $312.4M |
| FY2025 | $1.5B | $233.6M |
Cash flows
FY2025: $390.1M from operations, $348.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $281.8M | $263.4M |
| FY2023 | $305.3M | $258.7M |
| FY2024 | $544.8M | $465.1M |
| FY2025 | $390.1M | $348.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.5B+0.5%1Y
- EBITDA
- $403.6M-21.7%1Y
- Net profit
- $233.6M-25.2%1Y
- Cash from operations
- $390.1M-28.4%1Y
- Free cash flow
- $348.6M-25.0%1Y
- Revenue CAGR, 3Y
- 18.1%
- Net profit CAGR, 3Y
- 102.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.5B | $403.6M | $233.6M | $348.6M | 21.4% | +0.5% | -25.2% |
Monthly returns
Month-by-month returns of LNTH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.2B |
| Current assets | $900.0M |
| Non-current assets | $1.3B |
| Liabilities | $1.1B |
| Current liabilities | $333.4M |
| Non-current liabilities | $804.2M |
| Equity | $1.1B |
| Paid-in capital | $888.3M |
| Retained earnings | $679.5M |
| Treasury stock | $477.4M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; LNTH highlighted.
P/E against peers
LNTH trades at 28.7x earnings against a peer median of -13.3x.
Not shown (no positive earnings and no EV / Sales): Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc.LNTHthis company | $6.7B | 28.7x | 6.1x | 21.4% | 17.2x |
| HealthEquity, Inc.HQY | $7.2B | 33.4x | 3.4x | 10.2% | 16.1x |
| Oscar Health, Inc.OSCR | $7.1B | -16.1x | 7.3x | -45.3% | — |
| Vaxcyte, Inc.PCVX | $7.0B | -9.2x | 2.6x | -28.5% | -7.8x |
| Apogee Therapeutics, Inc.APGE | $6.9B | -26.8x | 7.6x | -28.3% | -23.7x |
| Spyre Therapeutics, Inc.SYRE | $6.8B | — | 9.5x | -21.7% | — |
| Arcellx, Inc.ACLX | $6.7B | -29.4x | 16.7x | -56.9% | -30.2x |
| Immunovant, Inc.IMVT | $6.7B | -13.3x | 7.9x | -59.3% | -10.9x |
| Hims & Hers Health, Inc.HIMS | $6.5B | 50.5x | 12.0x | 23.7% | 46.1x |
| Peer median | — | -13.3x | 7.7x | -28.4% | -9.3x |
Year-to-date ROI
LNTH since 1 January, against earlier years.
Historical volatility
LNTH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 3.9% |
| FY2023 | 28.1% |
| FY2024 | 29.2% |
| FY2025 | 20.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.5B |
| Cost of revenueCost Of Revenue | $599.7M |
| Gross profitGross Profit | $942.0M |
| Operating expensesOperating Expense | $626.4M |
| Research and developmentResearch And Development | $177.3M |
| Selling, general and administrativeSelling General And Administration | $453.8M |
| Other operating expensesOther Operating Expenses | -$4.7M |
| Total expensesTotal Expenses | $1.2B |
| Operating incomeOperating Income | $315.6M |
| Interest and other | |
| Pretax incomePretax Income | $313.8M |
| TaxTax Provision | $80.2M |
| Net incomeNet Income | $233.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.2B |
| Current assetsCurrent Assets | $900.0M |
| Non-current assetsTotal Non Current Assets | $1.3B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.1B |
| Current liabilitiesCurrent Liabilities | $333.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $804.2M |
| EquityTotal Equity Gross Minority Interest | $1.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $390.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $390.1M |
| Net income, continuing operationsNet Income From Continuing Operations | $233.6M |
| Depreciation and amortisationDepreciation And Amortization | $70.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $70.1M |
| Depreciation | $70.1M |
| Stock-based compensationStock Based Compensation | $85.6M |
| Deferred taxDeferred Tax | $21.8M |
| Deferred income taxDeferred Income Tax | $21.8M |
| Operating gains and lossesOperating Gains Losses | -$5.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | -$5.0M |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $8.6M |
| Asset impairmentAsset Impairment Charge | -$4.7M |
| Provision and write off of assetsProvisionand Write Offof Assets | $2.2M |
| Change in working capitalChange In Working Capital | -$44.2M |
| Other non-cash itemsOther Non Cash Items | $22.2M |
| Investing cash flowInvesting Cash Flow | -$627.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$627.2M |
| Capital expenditureCapital Expenditure | -$41.5M |
| Capital expenditure (reported)Capital Expenditure Reported | -$36.1M |
| AcquisitionsPurchase Of Business | -$585.7M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$585.7M |
| Purchase of intangiblesPurchase Of Intangibles | -$5.4M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$5.4M |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | -$316.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$316.6M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$1.1M |
| Net debt issuedNet Issuance Payments Of Debt | -$1.1M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$1.1M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$1.1M |
| Shares issuedIssuance Of Capital Stock | $3.7M |
| Common stock issuedCommon Stock Issuance | $3.7M |
| Net common stock issuedNet Common Stock Issuance | -$296.3M |
| Common stock repurchasedCommon Stock Payments | -$300.0M |
| Share buybacksRepurchase Of Capital Stock | -$300.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $7.2M |
| Other financing chargesNet Other Financing Charges | -$26.3M |
| Change in cashChanges In Cash | -$553.6M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -5.0% |
| Cash at the start of the yearBeginning Cash Position | $914.5M |
| Cash at the end of the yearEnd Cash Position | $360.8M |
| Free cash flowFree Cash Flow | $348.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Lantheus Holdings, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read